trending Market Intelligence /marketintelligence/en/news-insights/trending/gplbxZ3bVkEz3pevSTm3aQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Trillium closes common, preferred stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Trillium closes common, preferred stock offering

Trillium Therapeutics Inc. closed an underwritten public offering of 2,750,000 common shares and 3,250,000 series II nonvoting convertible first preferred shares at $5 apiece with gross proceeds of $30 million.

The company plans to use the net proceeds to advance and expand the current phase 1 trial of SIRPaFc in patients with advanced hematologic malignancies, as well as the solid tumor phase 1 trial of SIRPaFc in patients with relapsed and refractory, percutaneously accessible cancers through the dose escalation and expansion phases.

In addition, Trillium will use the proceeds to initiate and conduct a phase 1 trial for TTI-622, with dose escalation and expansion phase focused on combination treatment and for general corporate and working capital purposes.

Cowen acted as the sole book-running manager for the offering, with Ladenburg Thalmann as co-manager.